Kiromic BioPharma, Inc.

Cargo Therapeutics’ decision to end all development for its allogeneic cell therapy technology platform and its cancer cell therapy candidates is not the kind of news the biopharmaceutical sector need

Kiromic BioPharma, Inc. has had a tricky time so far, having had to close a handful of clinical trials of its T-cell therapies owing to poor patient accrual and undergoing delisting from the NASDAQ l

Initial public offerings in the US have been remarkable in 2020 with 70 biopharmaceutical company IPOs so far this year compared with the full-year 2019 total of 50 first-time offerings. However, whil